Verified ComparisonLast updated: 23 April 2026
Retatrutide vs Semaglutide
Retatrutide and semaglutide both target metabolic disease, but through different receptor sets. This comparison weights evidence quality, safety clarity and regulatory status alongside effect sizes.
Retatrutide
Metabolic
4.8/ 5
A+
Semaglutide
Metabolic
4.3/ 5
A−
Editor's note
Retatrutide leads on weight-loss potential in available trials. Semaglutide leads on length and breadth of clinical evidence.
| Criterion | Retatrutide | Semaglutide |
|---|---|---|
| Mechanism | GLP-1 + GIP + glucagon | GLP-1 |
| Weight loss in trials | Highest reported in class | Substantial, well-replicated |
| Cardiovascular outcomes | Trials ongoing | Established benefit (SELECT) |
| Regulatory status (AU) | Investigational | Approved for T2D and weight management |
| Length of evidence base | Phase II/III | Multi-year post-approval data |
| Adverse event profile | GI events common | GI events common |
Frequently asked questions
Semaglutide is registered. Retatrutide is investigational at the time of this comparison.
Want to read the full reviews?